Key Points
- Enovis insider Oliver Engert bought 1,000 shares on June 15 at an average price of $20.92, bringing his direct holdings to 53,640 shares. The purchase was disclosed in an SEC filing.
- Engert has been actively buying lately, with additional purchases of 1,200 shares on June 11, 1,000 shares on June 10, and 1,000 shares on June 1. In total, these recent trades signal continued insider confidence.
- Enovis reported strong quarterly results, beating both earnings and revenue estimates, and analysts currently rate the stock a Moderate Buy with an average price target of $44.50. The stock was up 2.8% and opened at $21.56.
Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert bought 1,000 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average price of $20.92 per share, with a total value of $20,920.00. Following the completion of the purchase, the insider directly owned 53,640 shares of the company's stock, valued at $1,122,148.80. This represents a 1.90% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Oliver Engert also recently made the following trade(s):
- On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The shares were acquired at an average price of $21.62 per share, with a total value of $25,944.00.
- On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average cost of $23.00 per share, with a total value of $23,000.00.
- On Monday, June 1st, Oliver Engert bought 1,000 shares of Enovis stock. The stock was acquired at an average cost of $22.22 per share, for a total transaction of $22,220.00.
Enovis Stock Up 2.8%
Shares of NYSE ENOV opened at $21.56 on Wednesday. The firm's 50-day simple moving average is $23.97 and its 200 day simple moving average is $24.44. Enovis Corporation has a 12-month low of $20.55 and a 12-month high of $36.82. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -1.08 and a beta of 1.38.
Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts' consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Enovis
Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Enovis by 2.0% in the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company's stock worth $197,945,000 after acquiring an additional 125,460 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock worth $90,156,000 after buying an additional 51,201 shares during the period. Rubric Capital Management LP acquired a new position in shares of Enovis in the third quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY raised its holdings in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock worth $40,420,000 after purchasing an additional 732,917 shares during the last quarter. Finally, River Road Asset Management LLC lifted its position in shares of Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock worth $39,621,000 after purchasing an additional 46,289 shares during the period. Institutional investors and hedge funds own 98.45% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on ENOV. Wells Fargo & Company cut their target price on shares of Enovis from $42.00 to $40.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. Evercore reiterated an "outperform" rating and issued a $36.00 price target on shares of Enovis in a research note on Friday, May 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Enovis in a research note on Friday, April 10th. William Blair started coverage on Enovis in a research report on Friday, April 17th. They issued an "outperform" rating for the company. Finally, Needham & Company LLC lifted their target price on shares of Enovis from $49.00 to $52.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $44.50.
Get Our Latest Stock Report on Enovis
Enovis Company Profile
(
Get Free Report)
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
